PMA device
LifeStent Vascular Stent System
Bard Peripheral Vascular, Inc. · Stent, Superficial Femoral Artery (NIP, Class III) · First FDA decision Jun 11, 2010, newest Jul 27, 2023Peripheral artery disease
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
11
PMA pathway
Device trials
14
Naming "LifeStent"
MAUDE reports
1,661
Brand "LifeStent", since 2015
PubMed studies
20
Mentioning "LifeStent"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing LifeStent Vascular Stent System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 11 decisions filed under this name.
- LifeStent Vascular Stent SystemPMA supplement
P070014-S065 · Decided Jul 27, 2023 · 156 days after receipt · Normal 180 Day Track No User Fee
Device type: STENT, SUPERFICIAL FEMORAL ARTERY (NIP) · Cardiology
5 more FDA decisions with a free account
Older decisions: P070014-S020, P070014-S018, P070014-S014, P070014-S010, P070014-S007
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R8Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R7Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R6Updated Sep 21, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085R3Updated Sep 21, 2026
- Carotid Artery Stenting in Post-Approval StudiesNational analysisReview closedCAG-00259NUpdated Sep 17, 2026
- Carotid Artery StentingNational analysisReview closedCAG-00085RUpdated Sep 17, 2026
- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with StentingNational analysisReview closedCAG-00085NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "LifeStent", any status and sponsor, newest update first.
- Self-expanding Nitinol Stents of High vs. Low Chronic Outward Force in De-novo Femoropopliteal Occlusive Arterial LesionsStatus unknown
Medical University of ViennaAcademic, hospital or other
NCT03097679 · 86 participants · Start Oct 1, 2015 · Primary completion Jul 31, 2019
Device: Pulsar Stent; LifeStent Flexstar Vascular Stent · For: Stent Restenosis; Intimal Hyperplasia
Sites: Vienna, Austria
13 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "LifeStent", and for the whole product code for context.
This brand
1,661 reports: 1,063 malfunction, 580 injury, 18 death
Whole product code NIP
9,363 reports: 4,911 malfunction, 4,303 injury, 147 death
Newest reports for this brand
- Lifestent 5F Vascular StentMalfunction
Angiomed GmbH & Co. Medizintechnik KG
9681442-2026-00252 · Received Oct 23, 2026 · Event dated Oct 5, 2026
Device type: Stent, Superficial Femoral Artery (NIP)
Device problem as coded: Fracture
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "LifeStent"[tiab]. The summary above synthesizes these.
- [Comparative study on the mechanical properties of lower limb arterial stents under various deformation modes].
Wang T, Feng H, Wang K · Sheng Wu Yi Xue Gong Cheng Xue Za Zhi · 2021
- Corrosion resistance, surface evaluation, and geometric design comparison of five self-expanding nitinol stents used in clinical practice.
Morrison JW, Pelletier MH, Rives A, et al. · J Endovasc Ther · 2014Comparative Study
- Fracture of self-expanding nitinol stents stressed in vitro under simulated intravascular conditions.
Nikanorov A, Smouse HB, Osman K, et al. · J Vasc Surg · 2008Comparative Study, Research Support, Non-U.S. Gov't
- Novel Nitinol Stent for Lesions up to 24 cm in the Superficial Femoral and Proximal Popliteal Arteries: 24-Month Results From the TIGRIS Randomized Trial.
Laird JR, Zeller T, Loewe C, et al. · J Endovasc Ther · 2018Multicenter Study, Randomized Controlled Trial
- Early results with LifeStent implantation in RESILIENT and non-RESILIENT inclusion criteria patients.
Stone PA, Campbell JE, Fischer R, et al. · Vascular · 2015
- Three-Year Clinical Outcomes Following Implantation of LifeStent Self-Expanding Nitinol Stents in Patients With Femoropopliteal Artery Lesions.
Tan M, Takahara M, Soga Y, et al. · Angiology · 2022Multicenter Study
- Comparison of second-generation stents for application in the superficial femoral artery: an in vitro evaluation focusing on stent design.
Müller-Hülsbeck S, Schäfer PJ, Charalambous N, et al. · J Endovasc Ther · 2010Comparative Study, Research Support, Non-U.S. Gov't
- Evaluation of Nitinol Stents Using a 3-Dimensional Printed Superficial Femoral Artery Model: A Preliminary Study.
Girsowicz E, Georg Y, Seiller H, et al. · Ann Vasc Surg · 2016Comparative Study, Evaluation Study
- NITINOL MATERIAL PROPERTIES OF 11 COMMERCIAL PERIPHERAL STENTS DETERMINED USING INVERSE COMPUTATIONAL ANALYSIS.
Anttila E, Maleckis K, Jadidi M, et al. · bioRxiv · 2025Preprint
- The Vascular Quality Initiative assessment of the Bard Lifestent for the treatment of popliteal artery occlusive disease.
Bertges DJ, Eldrup-Jorgensen J, Eskandari MK, et al. · J Vasc Surg · 2023Multicenter Study, Research Support, Non-U.S. Gov't
- Performance characteristics of modern self-expanding nitinol stents indicated for SFA.
Schmidt W, Wissgott C, Andresen R, et al. · Rofo · 2011Comparative Study
- Self-expanding nitinol stents of high versus low chronic outward force in de novo femoropopliteal occlusive arterial lesions (BIOFLEX-COF trial): study protocol for a randomized controlled trial.
Wressnegger A, Kaider A, Funovics MA · Trials · 2017Comparative Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code NIP.
- GORE VIABAHN EndoprosthesisW. L. Gore & Associates, Inc. · PMA 2022
- Supera Peripheral Stent SystemAbbott Vascular (Idef Technologies Inc) · PMA 2025
- Everflex Self-Expanding Peripheral Stent System (Everflex)Medtronic Vascular, Inc. · PMA 2025
- Innova Vascular Self-Expanding Stent SystemBoston Scientific Corporation · PMA 2021
- BioMimics 3D Vascular Stent SystemVeryan Medical, Ltd. · PMA 2025
- Bard Lifestent Vascular Stent SystemBard Peripheral Vascular, Inc. · PMA 2016
- Astron Pulsar and Pulsar-18 Stent SystemsBiotronik AG · PMA 2018
- Misago Peripheral Self-Expanding Stent SystemTerumo Medical Corporation · PMA 2017
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.